PL2167128T3 - Skonstruowane metodami inżynierii hybrydowe przeciwciała skierowane przeciwko integrynie alfa-v - Google Patents

Skonstruowane metodami inżynierii hybrydowe przeciwciała skierowane przeciwko integrynie alfa-v

Info

Publication number
PL2167128T3
PL2167128T3 PL08784834T PL08784834T PL2167128T3 PL 2167128 T3 PL2167128 T3 PL 2167128T3 PL 08784834 T PL08784834 T PL 08784834T PL 08784834 T PL08784834 T PL 08784834T PL 2167128 T3 PL2167128 T3 PL 2167128T3
Authority
PL
Poland
Prior art keywords
alpha
hybrid antibodies
engineered anti
integrin hybrid
integrin
Prior art date
Application number
PL08784834T
Other languages
English (en)
Inventor
Simon Goodman
Diane Hahn
Francesc Mitjans
Jaume Adan
Kin-Ming Lo
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL2167128T3 publication Critical patent/PL2167128T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL08784834T 2007-07-17 2008-07-17 Skonstruowane metodami inżynierii hybrydowe przeciwciała skierowane przeciwko integrynie alfa-v PL2167128T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07013964 2007-07-17
PCT/EP2008/005852 WO2009010290A2 (en) 2007-07-17 2008-07-17 Engineered anti-alpha v- integrin hybrid antibodies
EP08784834A EP2167128B1 (en) 2007-07-17 2008-07-17 Engineered anti-alpha v- integrin hybrid antibodies

Publications (1)

Publication Number Publication Date
PL2167128T3 true PL2167128T3 (pl) 2013-03-29

Family

ID=40029330

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08784834T PL2167128T3 (pl) 2007-07-17 2008-07-17 Skonstruowane metodami inżynierii hybrydowe przeciwciała skierowane przeciwko integrynie alfa-v

Country Status (19)

Country Link
US (1) US8562986B2 (pl)
EP (2) EP2526967A1 (pl)
JP (1) JP5341889B2 (pl)
KR (1) KR101559596B1 (pl)
CN (1) CN101687039B (pl)
AU (1) AU2008277907B2 (pl)
BR (1) BRPI0815567B8 (pl)
CA (1) CA2693863C (pl)
CY (1) CY1113493T1 (pl)
DK (1) DK2167128T3 (pl)
EA (1) EA019485B1 (pl)
ES (1) ES2395799T3 (pl)
HR (1) HRP20120949T1 (pl)
IL (1) IL203269A (pl)
PL (1) PL2167128T3 (pl)
PT (1) PT2167128E (pl)
SI (1) SI2167128T1 (pl)
WO (1) WO2009010290A2 (pl)
ZA (1) ZA201001124B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2747937C (en) 2008-12-23 2019-02-26 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
EA032728B1 (ru) 2009-08-19 2019-07-31 Мерк Патент Гмбх Антитела для выявления комплексов интегрина в ffpe материале
WO2012107211A1 (en) 2011-02-11 2012-08-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of prostate cancer
CA2923145C (en) * 2013-09-05 2025-09-16 Amgen Inc. MOLECULES CONTAINING FCS AND EXHIBITING PREDICTABLE, UNIFORM AND REPRODUCIBLE GLYCOFORM PROFILES
WO2016041614A1 (en) 2014-09-17 2016-03-24 Merck Patent Gmbh A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof
ES2897782T3 (es) 2014-09-17 2022-03-02 Merck Patent Gmbh Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
PL3221346T3 (pl) 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
WO2017088974A2 (en) * 2015-11-23 2017-06-01 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
HK1254295A1 (zh) * 2015-11-23 2019-07-19 默克专利股份有限公司 用於治疗纤维化和/或纤维化病症的抗-αＶ整合素抗体
US20190242908A1 (en) 2016-09-08 2019-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating nephrotic syndrome
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
KR20190095936A (ko) 2016-12-14 2019-08-16 프로제너티, 인크. 인테그린 저해제로의 위장관 질환의 치료
KR20190113870A (ko) 2017-02-02 2019-10-08 메르크 파텐트 게엠베하 항체 도메인의 바람직한 페어링
CN108948206B (zh) * 2017-05-23 2022-08-23 赵磊 一种抗egfr/pd-1双靶向抗体、其制备方法及用途
US11623963B2 (en) 2017-10-03 2023-04-11 Merck Patent Gmbh Cysteine engineered antigen-binding molecules
WO2019089544A1 (en) * 2017-11-01 2019-05-09 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
AU2019362602A1 (en) 2018-10-19 2021-06-03 Merck Patent Gmbh Abituzumab for the treatment of colorectal cancer
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN114366749B (zh) * 2020-10-15 2023-06-30 中国人民解放军海军军医大学 整合素抑制剂在制备治疗肾癌的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK281143B6 (sk) * 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
DE69531187T2 (de) 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
JP3461945B2 (ja) 1994-12-26 2003-10-27 株式会社日本製鋼所 高低圧一体型タービンロータの製造方法
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
EP1051432B1 (en) * 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
AU2002256624B2 (en) 2001-02-19 2007-12-06 Merck Patent Gmbh Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
EP1575516B1 (en) * 2002-11-26 2012-05-30 Abbott Biotherapeutics Corp. Chimeric and humanized antibodies to alpha5 beta1 integrin that modulate angiogenesis
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
KR20060002667A (ko) 2004-07-03 2006-01-09 삼성전자주식회사 디스크 댐퍼와 디스크 프로텍터를 구비한 하드 디스크드라이브
EP2270050B1 (en) * 2005-12-30 2013-06-05 Merck Patent GmbH Anti-CD19 antibodies with reduced immunogenicity
US7669429B2 (en) 2006-01-19 2010-03-02 Bassler Sr G Scott Rapid food chiller

Also Published As

Publication number Publication date
PT2167128E (pt) 2013-01-24
US8562986B2 (en) 2013-10-22
EP2167128A2 (en) 2010-03-31
CN101687039B (zh) 2014-04-16
ES2395799T3 (es) 2013-02-15
EP2526967A1 (en) 2012-11-28
JP2010533480A (ja) 2010-10-28
AU2008277907A1 (en) 2009-01-22
KR101559596B1 (ko) 2015-10-12
DK2167128T3 (da) 2012-12-03
AU2008277907B2 (en) 2013-08-22
CN101687039A (zh) 2010-03-31
KR20100057010A (ko) 2010-05-28
ZA201001124B (en) 2010-11-24
WO2009010290A3 (en) 2009-04-09
BRPI0815567B8 (pt) 2021-05-25
CA2693863C (en) 2017-10-03
BRPI0815567A2 (pt) 2015-02-18
JP5341889B2 (ja) 2013-11-13
EA019485B1 (ru) 2014-04-30
CA2693863A1 (en) 2009-01-22
EA201070150A1 (ru) 2010-08-30
CY1113493T1 (el) 2016-06-22
US20100254977A1 (en) 2010-10-07
IL203269A (en) 2014-11-30
WO2009010290A2 (en) 2009-01-22
EP2167128B1 (en) 2012-10-24
HRP20120949T1 (en) 2012-12-31
SI2167128T1 (sl) 2013-01-31
HK1143523A1 (en) 2011-01-07
BRPI0815567B1 (pt) 2019-06-04

Similar Documents

Publication Publication Date Title
ZA201001124B (en) Engineered anti-alpha v-integrin hybrid antibodies
HRP20182174T1 (hr) Anti-il-23p19 antitijela proizvedena genetičkim inženjeringom
ZA200905964B (en) Engineered anti-il-23R antibodies
GB0708002D0 (en) Antibodies
SI2200700T1 (sl) Nova protitelesa
GB0821100D0 (en) Antibodies
IL198424A0 (en) Hybrid immunoglobulins with moving parts
ZA201102119B (en) Improved antibody libraies
PT2146745E (pt) Anticorpo pentaespecífico
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
GB0718737D0 (en) Antibodies
ZA201006099B (en) Anti-tyrp1 antibodies
GB0707505D0 (en) Antibodies against il-25
GB0702888D0 (en) Novel Antibodies
IL205073A0 (en) Anti-bst2 antibody
GB0817891D0 (en) Antibodies against il-25
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
HK1126789A (en) Engineered anti-il-23r antibodies
HK1144582A (en) Engineered anti-tslpr antibodies
GB0724185D0 (en) Antibodies
GB0806230D0 (en) Antibodies
GB0823562D0 (en) Antibodies